Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Moodys
McKesson
Covington
Dow
Queensland Health
Healthtrust
QuintilesIMS
UBS

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,972,990

« Back to Dashboard

Which drugs does patent 5,972,990 protect, and when does it expire?

Patent 5,972,990 protects DIOVAN and is included in one NDA.

Protection for DIOVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in eight countries.
Summary for Patent: 5,972,990
Title: Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
Abstract:The invention involves a method for treating a human survivor of a heart attack and provides further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor. The inhibitor may be used on its own, or in conjunction with other therapeutic compounds such as data blockers and thrombolytic agents. The preferred inhibitor is captopril.
Inventor(s): Pfeffer; Marc A. (Chestnut Hill, MA), Pfeffer; Janice M. (Chestnut Hill, MA), Braunwald; Eugene (Weston, MA)
Assignee: Brigham and Women's Hospital, Inc. (Boston, MA)
Application Number:07/981,196
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 5,972,990

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis DIOVAN valsartan TABLET;ORAL 021283-004 Aug 14, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis DIOVAN valsartan TABLET;ORAL 021283-001 Jul 18, 2001 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis DIOVAN valsartan TABLET;ORAL 021283-002 Jul 18, 2001 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis DIOVAN valsartan TABLET;ORAL 021283-003 Jul 18, 2001 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,972,990

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,952,305 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims ➤ Subscribe
5,977,160 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,972,990

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 4281093 ➤ Subscribe
Canada 2117782 ➤ Subscribe
Germany 69333362 ➤ Subscribe
Denmark 0641218 ➤ Subscribe
European Patent Office 0641218 ➤ Subscribe
European Patent Office 1262175 ➤ Subscribe
Spain 2211867 ➤ Subscribe
Japan H07505884 ➤ Subscribe
World Intellectual Property Organization (WIPO) 9320839 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
UBS
Mallinckrodt
Dow
Argus Health
Medtronic
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot